Vertex Pharmaceuticals Incorporated (VRTX)
VRTX moved a median of +0.10% 30 minutes after news, and +0.09% by the close. How VRTX actually reacts to news — the realized, point-in-time move the market made, measured across 733 labeled events over the last three years with zero look-ahead.
VRTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 53% | 733 |
| 30-min | +0.10% | 55% | 733 |
| 60-min | +0.15% | 58% | 733 |
| to close | +0.09% | 54% | 733 |
| Middle 50% of VRTX reactions | -0.41% to +0.65% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 733 |
Half of all Vertex Pharmaceuticals Incorporated news events land between -0.41% and +0.65% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VRTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 64 | +0.35% | 66% | +0.26% |
| Analyst downgrades | 54 | -0.22% | 39% | -0.89% |
| Coverage initiations | 28 | +0.24% | 64% | +0.66% |
| Rating reiterations | 217 | +0.01% | 51% | +0.05% |
| Price-target raises | 71 | -0.03% | 47% | +0.06% |
| Price-target cuts | 32 | -0.16% | 38% | -0.12% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how VRTX ranks against every other measured name →
That’s how VRTX usually reacts — get an email when it moves on news →Email me when VRTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRTX's baseline. Nothing else.
Recent VRTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference | Press release | Business Wire | -0.03% | -0.07% | |
| Vertex to Announce Third Quarter 2026 Financial Results November 2nd | Press release | Business Wire | -0.24% | +0.02% | |
| Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial | Press release | Business Wire | -1.50% | -1.28% | |
| Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain | Press release | Business Wire | -0.86% | -1.02% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | +0.78% | |
| Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team | Press release | Business Wire | +0.25% | -0.17% | |
| Vertex to Participate in Upcoming September Investor Conferences | Press release | Business Wire | +0.18% | +0.95% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.19% | -0.55% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +1.57% | |
| Vertex Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +2.12% | +1.57% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | -1.46% | |
| Vertex to Announce Second Quarter 2026 Financial Results on August 3rd | Press release | Business Wire | +0.12% | -4.71% | |
| Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis | Press release | Canada Newswire | +0.15% | +2.41% | |
| Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia | Press release | Business Wire | -0.08% | +4.82% | |
| Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions | Press release | Business Wire | -0.27% | +1.72% | |
| Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | Press release | Business Wire | +0.19% | -0.17% | |
| Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | Press release | Business Wire | +1.48% | +1.56% | |
| Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy | Press release | Business Wire | +0.04% | -0.34% | |
| Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum | Press release | PR Newswire | +0.75% | +2.75% | |
| Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults | Press release | Canada Newswire | -0.05% | +1.05% | |
| Form 8-K VERTEX PHARMACEUTICALS For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -0.71% | |
| Form S-8 VERTEX PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | -0.50% | -0.71% | |
| Form S-8 POS VERTEX PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | -0.50% | -0.71% | |
| Vertex to Participate in Upcoming May Investor Conferences | Press release | Business Wire | -0.23% | +2.06% | |
| Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany | Press release | Business Wire | +0.41% | +1.08% | |
| Form 10-Q VERTEX PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.41% | +1.08% | |
| Form 8-K VERTEX PHARMACEUTICALS For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -2.12% | -2.20% | |
| Vertex Reports First Quarter 2026 Financial Results | Press release | Business Wire | -2.12% | -2.20% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +0.83% | |
| Form DEFA14A VERTEX PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.50% | +0.83% | |
| Vertex to Announce First Quarter 2026 Financial Results on May 4th | Press release | Business Wire | -1.29% | -0.84% | |
| Form ARS VERTEX PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.07% | -0.80% | |
| Form DEF 14A VERTEX PHARMACEUTICALS For: May 13 | SEC filing · Form DEF | SEC EDGAR | -0.07% | -0.80% | |
| Form DEFA14A VERTEX PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.07% | -0.80% | |
| Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States | Press release | Business Wire | +0.58% | -0.42% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | -0.42% | |
| Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy | Press release | Business Wire | +3.04% | +3.41% | |
| Vertex to Participate in Upcoming March Investor Conferences | Press release | Business Wire | +0.12% | -0.13% | |
| Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures | Press release | Business Wire | -0.23% | -2.65% | |
| Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 | Press release | Business Wire | -0.51% | -0.71% | |
| Form 10-K VERTEX PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.98% | -2.48% | |
| Form 8-K VERTEX PHARMACEUTICALS For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | +3.89% | |
| Vertex Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +3.08% | +3.89% | |
| WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager | Press release | PR Newswire | +0.26% | -1.34% | |
| Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs | Press release | Business Wire | +0.57% | -0.70% | |
| Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th | Press release | Business Wire | +0.47% | +4.68% | |
| Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings | Press release | Business Wire | -1.42% | -0.10% | |
| Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 | Press release | Business Wire | +0.02% | -0.27% | |
| From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes | Press release | GlobeNewswire | -0.06% | +0.06% | |
| Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions | Press release | Business Wire | +0.18% | -2.99% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRTX section they belong to.
Where else VRTX is measured.
VRTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CESCA THERAPEUTICS INC COMMON (KOOL) | 736 | -0.01% | 37% |
| AIMMUNE THERAPEUTICS (AIMT) | 734 | -0.29% | 40% |
| AbbVie Inc. (ABBV) | 731 | 0.00% | 50% |
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vertex Pharmaceuticals Incorporated's median reaction calculated?
Every labeled VRTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 733 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of VRTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.